title: Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.
abstract: OBJECTIVE
  To observe the effect of prophylactic intraocular pressure (IOP)-lowering medication (brinzolamide) on IOP after ranibizumab intravitreal injections (IVIs).
  
  
  METHODS
  This prospective case-control study included 352 eyes from 352 patients (1 eye per patient) who were treated with ranibizumab intravitreal injection and divided randomly into two groups. Two hundred and three patients in control group only received the ranibizumab IVI, but 149 patients in case group received one drop of prophylactic intraocular brinzolamide preinjection. The IOP was measured by noncontact tonometer before injection, at 10, 30, 120 min and 1 day after injection in a sitting position.
  
  
  RESULTS
  The mean IOP measured before injection, at 10, 30, 120 min and 1 day after injection individually were 15.79 ± 2.21 mmHg, 19.33 ± 4.86 mmHg, 16.64 ± 2.93 mmHg, 16.17 ± 3.13 mmHg, and 15.07 ± 2.55 mmHg in case group and were 15.82 ± 2.57 mmHg, 21.34 ± 5.88 mmHg, 18.17 ± 4.06 mmHg, 17.59 ± 4.42 mmHg, and15.48 ± 2.92 mmHg in control group. Comparing two groups, the mean increase on IOP was statistically significant at 10, 30, 120 min postinjection (P < 0.05).
  
  
  CONCLUSIONS
  IVI of ranibizumab causes a considerable short-term transient rise on IOP in most patients. The effect of prophylactic IOP-lowering medication on IOP after IVIs can be statistically significant from 10 min to 2 h after IVIs.
authors.affiliation: Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Beijing, P. R. China.
authors.forename: Shuang
authors.initials: S
authors.lastname: Song
authors.affiliation: Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Beijing, P. R. China.
authors.forename: Xiao-Bing
authors.initials: XB
authors.lastname: Yu
authors.affiliation: Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Beijing, P. R. China.
authors.forename: Hong
authors.initials: H
authors.lastname: Dai
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000503:physiopathology / Q000517:prevention & control*; D011446:Prospective Studies; D000069579:Ranibizumab / Q000008:administration & dosage*; D012164:Retinal Diseases / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage*; D013843:Thiazines / Q000008:administration & dosage*; D014065:Tonometry, Ocular; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013843:Thiazines; C111827:brinzolamide; D000069579:Ranibizumab